Virtual hepatic venous pressure gradient (vHVPG), a novel noninvasive approach to assess portal hypertension, is shown to correlate well with the gold-standard invasive method in a recent Chinese study.
New endoscopic technologies have improved outcomes for patients with upper gastrointestinal bleeding (UGIB), according to Professor James Lau from the Chinese University of Hong Kong, who reviewed current treatment practices and latest advances at the Asian Pacific Digestive Week (APDW) 2017 held recently in Hong Kong.
Sodium phosphate (NaP) tablets for bowel preparation prior to colonoscopy are safe, better tolerated by patients, and provide equivalent and possibly superior colon cleansing compared with standard polyethylene glycol (PEG) solution, a Korean study has found.
Genotypic resistance-guided therapy is no better than traditional empiric therapy for treating patients with refractory Helibacter pylori infection. Researchers found no significant difference in eradication rate between the two strategies when used in the third-line setting.
While bleeding from the small intestine is relatively uncommon, it often presents a diagnostic challenge. Speaking at the Asian Pacific Digestive Week (APDW) 2017 held recently in Hong Kong, Dr Simon Lo from the Cedars Sinai Medical Center in Los Angeles, California, US, reviewed current guidelines and practices with a special focus on common pitfalls.
An index of three liver-specific microRNAs (the MiR-B Index) could serve as a biomarker of spontaneous or treatment-induced transition from active to inactive chronic hepatitis B virus (HBV) infection, facilitating disease monitoring and testing of new antivirals, according to Dr Mauricia Brunetto from the University of Pisa, Italy, who spoke recently at the Asian Pacific Digestive Week (APDW) 2017 in Hong Kong.
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.
Men with advanced prostate cancer who have pre-existing cardiovascular disease (CVD) may have an elevated mortality risk after treatment with abiraterone acetate compared with men who do not have CVD, according to a study presented at AACR 2019.